Who is sponsoring NCT04089605?

NCT04089605 is sponsored by Far Eastern Memorial Hospital.

What condition does NCT04089605 study?

NCT04089605 studies Diabetic Macular Edema.

What drugs are being tested in NCT04089605?

Interventions: dexamethasone implant, Ranibizumab.

What is the status of NCT04089605?

NCT04089605 is currently COMPLETED.

Last reviewed 2019-09-13 · How we verify

Ranibizumab vs Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema

NCT04089605 PHASE4 COMPLETED

Vitrectomy is required for removal of vitreous hemorrhage or retinal traction tissue in some patients with proliferative diabetic retinopathy. Post-vitrectomy macular edema may occur in these diabetic patients. Intravitreal injections of anti-VEGF agents or corticosteroid are required for treating diabetic macular edema (DME) in vitrectomized eyes. Intraocular levels of various cytokines may alter in the diabetic eyes following vitrectomy. Pharmacokinetics may be different between various intraocular agents in vitrectomized eyes. Herein our study will prospectively randomize to compare the clinical behavior between intravitreal ranibizumab (IVR) and intravitreal dexamethasone implant (IDI) in vitrectomized patients with DME. To our knowledge, it is the first study involving such subject.

Details

Lead sponsor	Far Eastern Memorial Hospital
Phase	PHASE4
Status	COMPLETED
Enrolment	48
Start date	Thu Jun 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Diabetic Macular Edema

Interventions

dexamethasone implant
Ranibizumab

Countries

Taiwan